News
Nektar Therapeutics Q1 2024 GAAP EPS $(0.19) Beats $(0.20) Estimate, Sales $21.639M Beat $15.342M Estimate
9 May 24
Earnings, Earnings Beats, News
12 Health Care Stocks Moving In Tuesday's After-Market Session
7 May 24
Movers
Nektar Therapeutics Receives Letter That It Has Regained Compliance With Minimum Bid Price Requirement For Continued Listing On Nasdaq Capital Market - Filing
17 Apr 24
News
12 Health Care Stocks Moving In Thursday's Intraday Session
11 Apr 24
Movers
Jefferies Maintains Hold on Nektar Therapeutics, Raises Price Target to $1
6 Mar 24
News, Price Target, Analyst Ratings
Nektar Therapeutics Announces Initiation Of Phase 2b Clinical Study Evaluating Rezpegaldesleukin In Patients With Severe To Very Severe Alopecia Areata
5 Mar 24
Biotech, News, General
Press releases
Nektar Management to Present at Upcoming Investor Conferences
30 May 24
Press Releases
Nektar Therapeutics Reports First Quarter 2024 Financial Results
9 May 24
Earnings, Press Releases
Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets
2 May 24
Press Releases
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
22 Mar 24
Press Releases